BOND study: a randomised double-blind, placebo-controlled trial over 12 months to assess the effects of benfotiamine on morphometric, neurophysiological and clinical measures in patients with type 2 diabetes with symptomatic polyneuropathy

INTRODUCTION: Diabetic sensorimotor polyneuropathy (DSPN) affects approximately 30% of people with diabetes, while around half of cases are symptomatic. Currently, there are only few pathogenetically oriented pharmacotherapies for DSPN, one of which is benfotiamine, a prodrug of thiamine with a high...

Descripción completa

Detalles Bibliográficos
Autores principales: Bönhof, Gidon J, Sipola, Gundega, Strom, Alexander, Herder, Christian, Strassburger, Klaus, Knebel, Birgit, Reule, Claudia, Wollmann, Jan-Christoph, Icks, Andrea, Al-Hasani, Hadi, Roden, Michael, Kuss, Oliver, Ziegler, Dan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Diabetes and Endocrinology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8814806/
https://www.ncbi.nlm.nih.gov/pubmed/35115359
http://dx.doi.org/10.1136/bmjopen-2021-057142

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8814806/
https://www.ncbi.nlm.nih.gov/pubmed/35115359
http://dx.doi.org/10.1136/bmjopen-2021-057142

Ejemplares similares